Use of transient elastography to assess hepatic steatosis and fibrosis in patients with juvenile idiopathic arthritis during methotrexate treatment.
Hepatic fibrosis
Hepatic steatosis
Juvenile idiopathic arthritis
Methotrexate
Transient elastography
Journal
Clinical rheumatology
ISSN: 1434-9949
Titre abrégé: Clin Rheumatol
Pays: Germany
ID NLM: 8211469
Informations de publication
Date de publication:
08 Dec 2023
08 Dec 2023
Historique:
received:
15
08
2023
accepted:
26
11
2023
revised:
08
11
2023
medline:
8
12
2023
pubmed:
8
12
2023
entrez:
7
12
2023
Statut:
aheadofprint
Résumé
This study aimed to assess the prevalence and identify predictors of hepatic steatosis and fibrosis in patients with juvenile idiopathic arthritis (JIA) during methotrexate treatment. This cross-sectional study included JIA patients who had received methotrexate for > 1 year. Laboratory data including liver chemistry and lipid profiles were collected. Liver stiffness measurements (LSM) and controlled attenuation parameters (CAP) were determined by transient elastography. Significant hepatic fibrosis was defined as LSM > 7 kilopascal (kPa), and hepatic steatosis was defined as CAP > 225 decibel/meter (dB/m). Logistic regression analysis was performed to identify predictors associated with hepatic steatosis and fibrosis. Of 60 patients, 66.7% were female, and the median age (IQR) was 12.8 (10.6-15.0) years. The median duration of methotrexate usage (IQR) was 45 (22-85) months, and the median cumulative dose of methotrexate (IQR) was 3768 (1806-6466) mg. The median LSM (IQR) and CAP (IQR) were 4.1 (3.4-4.6) kPa and 191.0 (170.3-223.8) dB/m, respectively. No patients had transient elastography-defined hepatic fibrosis, whereas 21.7% had hepatic steatosis. A body mass index Z-score > 1 (OR 5.71 [95%CI 1.31-24.98], p = 0.021) and higher cumulative dose of methotrexate (OR 1.02 [95%CI 1.00-1.04], p = 0.041) were associated with hepatic steatosis, whereas the cumulative dose of steroids was not (OR 1.00 [95%CI 1.00-1.01], p = 0.097). Hepatic steatosis is common among JIA patients receiving methotrexate, but none had transient elastography-defined hepatic fibrosis. Overweight/obese JIA adolescents and patients with a high cumulative dose of methotrexate are at risk for hepatic steatosis. Key Points •Long-term low-dose methotrexate usage and the concomitant use of other DMARDs did not increase the risk of hepatic fibrosis in JIA patients. •The prevalence of hepatic steatosis in JIA patients receiving methotrexate was higher than in a healthy pediatric population. •Overweight/obesity and a higher cumulative dose of methotrexate were predictors of hepatic steatosis.
Identifiants
pubmed: 38062311
doi: 10.1007/s10067-023-06835-x
pii: 10.1007/s10067-023-06835-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s).
Références
Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J et al (2004) International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31:390–392
pubmed: 14760812
Ringold S, Angeles-Han ST, Beukelman T, Lovell D, Cuello CA, Becker ML et al (2019) 2019 American College of Rheumatology/Arthritis Foundation Guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis. Arthritis Care Res (Hoboken) 71(6):717–734. https://doi.org/10.1002/acr.23870
doi: 10.1002/acr.23870
pubmed: 31021516
Onel KB, Horton DB, Lovell DJ, Shenoi S, Cuello CA, Angeles-Han ST et al (2022) 2021 American College of Rheumatology Guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for oligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 74(4):521–537. https://doi.org/10.1002/acr.24853
doi: 10.1002/acr.24853
pubmed: 35233986
Salliot C, van der Heijde D (2009) Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 68(7):1100–1104. https://doi.org/10.1136/ard.2008.093690
doi: 10.1136/ard.2008.093690
pubmed: 19060002
Erickson AR, Reddy V, Vogelgesang SA, West SG (1995) Usefulness of the American College of Rheumatology recommendations for liver biopsy in methotrexate-treated rheumatoid arthritis patients. Arthritis Rheum 38(8):1115–1119. https://doi.org/10.1002/art.1780380814
doi: 10.1002/art.1780380814
pubmed: 7639808
Kremer JM, Furst DE, Weinblatt ME, Blotner SD (1996) Significant changes in serum AST across hepatic histological biopsy grades: prospective analysis of 3 cohorts receiving methotrexate therapy for rheumatoid arthritis. J Rheumatol 23(3):459–461
pubmed: 8832983
Castera L, Forns X, Alberti A (2008) Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 48(5):835–847. https://doi.org/10.1016/j.jhep.2008.02.008
doi: 10.1016/j.jhep.2008.02.008
pubmed: 18334275
Yoneda M, Imajo K, Eguchi Y, Fujii H, Sumida Y, Hyogo H et al (2013) Noninvasive scoring systems in patients with nonalcoholic fatty liver disease with normal alanine aminotransferase levels. J Gastroenterol 48(9):1051–1060. https://doi.org/10.1007/s00535-012-0704-y
doi: 10.1007/s00535-012-0704-y
pubmed: 23184095
Lee CK, Mitchell PD, Raza R, Harney S, Wiggins SM, Jonas MM (2018) Validation of transient elastography cut points to assess advanced liver fibrosis in children and young adults: the Boston Children’s Hospital experience. J Pediatr 198:84-89.e2. https://doi.org/10.1016/j.jpeds.2018.02.062
doi: 10.1016/j.jpeds.2018.02.062
pubmed: 29685617
pmcid: 6019197
Lertnawapan R, Chonprasertsuk S, Siramolpiwat S (2019) Association between cumulative methotrexate dose, non-invasive scoring system and hepatic fibrosis detected by FibroScan in rheumatoid arthritis patients receiving methotrexate. Int J Rheum Dis 22(2):214–221. https://doi.org/10.1111/1756-185X.13442
doi: 10.1111/1756-185X.13442
pubmed: 30565876
Ortolan A, Lorenzin M, Tadiotto G, Russo FP, Oliviero F, Felicetti M et al (2019) Metabolic syndrome, non-alcoholic fatty liver disease and liver stiffness in psoriatic arthritis and psoriasis patients. Clin Rheumatol 38(10):2843–2850. https://doi.org/10.1007/s10067-019-04646-7
doi: 10.1007/s10067-019-04646-7
pubmed: 31254236
Behairy Bel S, Sira MM, Zalata KR, el Salama SE, Abd-Allah MA (2016) Transient elastography compared to liver biopsy and morphometry for predicting fibrosis in pediatric chronic liver disease: does etiology matter? World J Gastroenterol 22(16):4238–4249. https://doi.org/10.3748/wjg.v22.i16.4238
doi: 10.3748/wjg.v22.i16.4238
Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G et al (2009) Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum 61(5):658–666. https://doi.org/10.1002/art.24516
doi: 10.1002/art.24516
pubmed: 19405003
Bulatović Calasan M, de Vries LD, Vastert SJ, Heijstek MW, Wulffraat NM (2014) Interpretation of the Juvenile Arthritis Disease Activity Score: responsiveness, clinically important differences and levels of disease activity in prospective cohorts of patients with juvenile idiopathic arthritis. Rheumatology (Oxford) 53(2):307–312. https://doi.org/10.1093/rheumatology/ket310
doi: 10.1093/rheumatology/ket310
pubmed: 24162034
de Onis M, Onyango AW, Borghi E, Siyam A, Nishida C, Siekmann J (2007) Development of a WHO growth reference for school-aged children and adolescents. Bull World Health Organ 85(9):660–667. https://doi.org/10.2471/blt.07.043497
doi: 10.2471/blt.07.043497
pubmed: 18026621
pmcid: 2636412
Vos MB, Abrams SH, Barlow SE, Caprio S, Daniels SR, Kohli R et al (2017) NASPGHAN Clinical Practice Guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children: recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr 64(2):319–334. https://doi.org/10.1097/MPG.0000000000001482
doi: 10.1097/MPG.0000000000001482
pubmed: 28107283
pmcid: 5413933
Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, & National Heart, Lung, and Blood Institute (2011) Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 128(Suppl 5):S213–S256. https://doi.org/10.1542/peds.2009-2107C
doi: 10.1542/peds.2009-2107C
Berends MA, Snoek J, de Jong EM et al (2007) Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: FibroTest predicts the presence and FibroScan predicts the absence of significant liver fibrosis. Liver Int 27(5):639–645. https://doi.org/10.1111/j.1478-3231.2007.01489.x
doi: 10.1111/j.1478-3231.2007.01489.x
pubmed: 17498249
Desai NK, Harney S, Raza R, Al-Ibraheemi A, Shillingford N, Mitchell PD et al (2016) Comparison of controlled attenuation parameter and liver biopsy to assess hepatic steatosis in pediatric patients. J Pediatr 173:160-164.e1. https://doi.org/10.1016/j.jpeds.2016.03.021
doi: 10.1016/j.jpeds.2016.03.021
pubmed: 27039224
pmcid: 5105890
Park SH, Choe JY, Kim SK (2010) Assessment of liver fibrosis by transient elastography in rheumatoid arthritis patients treated with methotrexate. Joint Bone Spine 77(6):588–592. https://doi.org/10.1016/j.jbspin.2010.02.024
doi: 10.1016/j.jbspin.2010.02.024
pubmed: 20471892
Montesinos MC, Takedachi M, Thompson LF, Wilder TF, Fernández P, Cronstein BN (2007) The antiinflammatory mechanism of methotrexate depends on extracellular conversion of adenine nucleotides to adenosine by ecto-5’-nucleotidase: findings in a study of ecto-5’-nucleotidase gene-deficient mice. Arthritis Rheum 56(5):1440–1445. https://doi.org/10.1002/art.22643
doi: 10.1002/art.22643
pubmed: 17469101
Yassin NA, Haroon M, Elhamshary A (2021) Methotrexate hepatotoxicity in children with juvenile idiopathic arthritis: a single-center study. Curr Rheumatol Rev 17(2):242–246. https://doi.org/10.2174/1573397116666201211123142
doi: 10.2174/1573397116666201211123142
pubmed: 33308133
Ortiz-Alvarez O, Morishita K, Avery G, Green J, Petty RE, Tucker LB et al (2004) Guidelines for blood test monitoring of methotrexate toxicity in juvenile idiopathic arthritis. J Rheumatol 31(12):2501–2506
pubmed: 15570658
Özdemir Çiçek S, Karaman ZF, Şahin N, Paç Kısaarslan A, Poyrazoğlu MH, Düşünsel R (2022) Evaluation of liver elasticity with shear-wave elastography in juvenile idiopathic arthritis patients receiving methotrexate. Pediatr Int 64(1):e15239. https://doi.org/10.1111/ped.15239
doi: 10.1111/ped.15239
pubmed: 36217648
Hashkes PJ, Balistreri WF, Bove KE, Ballard ET, Passo MH (1999) The relationship of hepatotoxic risk factors and liver histology in methotrexate therapy for juvenile rheumatoid arthritis. J Pediatr 134(1):47–52. https://doi.org/10.1016/s0022-3476(99)70371-9
doi: 10.1016/s0022-3476(99)70371-9
pubmed: 9880448
Katchamart W, Trudeau J, Phumethum V, Bombardier C (2009) Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis 68(7):1105–1112. https://doi.org/10.1136/ard.2008.099861
doi: 10.1136/ard.2008.099861
pubmed: 19054823
Bafna P, Sahoo RR, Hazarika K, Manoj M, Rungta S, Wakhlu A (2021) Prevalence of liver fibrosis by FibroScan in patients on long-term methotrexate therapy for rheumatoid arthritis. Clin Rheumatol 40(9):3605–3613. https://doi.org/10.1007/s10067-021-05678-8
doi: 10.1007/s10067-021-05678-8
pubmed: 33686476
Darabian S, Wade JP, Kur J, Wade SD, Sayre EC, Badii M (2022) Using FibroScan to assess for the development of liver fibrosis in patients with arthritis on methotrexate: a single-center experience. J Rheumatol 49(6):558–565. https://doi.org/10.3899/jrheum.211281
doi: 10.3899/jrheum.211281
pubmed: 35293340
Laharie D, Seneschal J, Schaeverbeke T, Doutre MS, Longy-Boursier M, Pellegrin JL et al (2010) Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case-control study. J Hepatol 53(6):1035–1040. https://doi.org/10.1016/j.jhep.2010.04.043
doi: 10.1016/j.jhep.2010.04.043
pubmed: 20801541
Erre GL, Cadoni ML, Meloni P, Castagna F, Mangoni AA, Piga M et al (2019) Methotrexate therapy is not associated with increased liver stiffness and significant liver fibrosis in rheumatoid arthritis patients: a cross-sectional controlled study with real-time two-dimensional shear wave elastography. Eur J Intern Med 69:57–63. https://doi.org/10.1016/j.ejim.2019.08.022
doi: 10.1016/j.ejim.2019.08.022
pubmed: 31474422
Güngörer V, Öztürk M, Özlü MY, Arslan Ş (2022) What is the impact of methotrexate on liver in patients with juvenile idiopathic arthritis? Results of liver SWE performed in a single centre. Mod Rheumatol 32(4):776–782. https://doi.org/10.1093/mr/roab064
doi: 10.1093/mr/roab064
pubmed: 34918139
Mărginean CO, Meliţ LE, Ghiga DV, Săsăran MO (2020) Reference values of normal liver stiffness in healthy children by two methods: 2D shear wave and transient elastography. Sci Rep 10(1):7213. https://doi.org/10.1038/s41598-020-64320-w
doi: 10.1038/s41598-020-64320-w
pubmed: 32350349
pmcid: 7190848
Etchell E, Jugé L, Hatt A, Sinkus R, Bilston LE (2017) Liver stiffness values are lower in pediatric subjects than in adults and increase with age: a multifrequency MR elastography study. Radiology 283(1):222–230. https://doi.org/10.1148/radiol.2016160252
doi: 10.1148/radiol.2016160252
pubmed: 27755913
Li DK, Khan MR, Wang Z, Chongsrisawat V, Swangsak P, Teufel-Schäfer U et al (2020) Normal liver stiffness and influencing factors in healthy children: an individual participant data meta-analysis. Liver Int 40(11):2602–2611. https://doi.org/10.1111/liv.14658
doi: 10.1111/liv.14658
pubmed: 32901449
Jain V, Poddar U, Negi TS, Saraswat VA, Krishnani N, Yachha SK et al (2020) Utility and accuracy of transient elastography in determining liver fibrosis: a case-control study. Eur J Pediatr 179(4):671–677. https://doi.org/10.1007/s00431-019-03561-y
doi: 10.1007/s00431-019-03561-y
pubmed: 31960149
Lahdenne P, Rapola J, Ylijoki H, Haapasaari J (2002) Hepatotoxicity in patients with juvenile idiopathic arthritis receiving longterm methotrexate therapy. J Rheumatol 29(11):2442–2445
pubmed: 12415606
van Ede AE, Laan RF, Rood MJ, Huizinga TW, van de Laar MA, van Denderen CJ et al (2001) Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 44(7):1515–1524. https://doi.org/10.1002/1529-0131(200107)44:7%3c1515::AID-ART273%3e3.0.CO;2-7
doi: 10.1002/1529-0131(200107)44:7<1515::AID-ART273>3.0.CO;2-7
pubmed: 11465701
van Ede AE, Laan RF, Blom HJ, De Abreu RA, van de Putte LB (1998) Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. Semin Arthritis Rheum 27(5):277–292. https://doi.org/10.1016/s0049-0172(98)80049-8
doi: 10.1016/s0049-0172(98)80049-8
pubmed: 9572710
Mori S, Arima N, Ito M, Fujiyama S, Kamo Y, Ueki Y (2018) Non-alcoholic steatohepatitis-like pattern in liver biopsy of rheumatoid arthritis patients with persistent transaminitis during low-dose methotrexate treatment. PLoS One 13(8):e0203084. https://doi.org/10.1371/journal.pone.0203084
doi: 10.1371/journal.pone.0203084
pubmed: 30142184
pmcid: 6108522
Erre GL, Castagna F, Sauchella A, Meloni P, Mangoni AA, Farina G et al (2021) Prevalence and risk factors of moderate to severe hepatic steatosis in patients with rheumatoid arthritis: an ultrasonography cross-sectional case-control study. Ther Adv Musculoskelet Dis 13:1759720x211042739. https://doi.org/10.1177/1759720X211042739
doi: 10.1177/1759720X211042739
pubmed: 34819999
pmcid: 8606981
Anderson EL, Howe LD, Jones HE, Higgins JP, Lawlor DA, Fraser A (2015) The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis. PLoS One 10(10):e0140908. https://doi.org/10.1371/journal.pone.0140908
doi: 10.1371/journal.pone.0140908
pubmed: 26512983
pmcid: 4626023
Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C (2006) Prevalence of fatty liver in children and adolescents. Pediatrics 118(4):1388–1393. https://doi.org/10.1542/peds.2006-1212
doi: 10.1542/peds.2006-1212
pubmed: 17015527
Sakthiswary R, Chan GY, Koh ET, Leong KP, Thong BY (2014) Methotrexate-associated nonalcoholic fatty liver disease with transaminitis in rheumatoid arthritis. ScientificWorldJournal 2014:823763. https://doi.org/10.1155/2014/823763
doi: 10.1155/2014/823763
pubmed: 24971392
pmcid: 4058155
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M (2016) Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64(1):73–84. https://doi.org/10.1002/hep.28431
doi: 10.1002/hep.28431
pubmed: 26707365
Gremese E, Carletto A, Padovan M, Atzeni F, Raffeiner B, Giardina AR et al (2013) Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine. Arthritis Care Res (Hoboken) 65(1):94–100. https://doi.org/10.1002/acr.21768
doi: 10.1002/acr.21768
pubmed: 22730143